Straits Times Index
3,327.18 +0.90 (+0.03%) Nikkei
39,535.56 +362.41 (+0.93%) Hang Seng
17,975.08 -97.82 (-0.54%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,979.83 +1,651.73 (+2.74%) CMC Crypto 200
1,284.64 +35.52 (+2.84%)
TARA Jun 2024 2.500 call
- GlobeNewswire
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grant of inducement non-qualified stock options to purchase an aggregate of 118,400 shares of common stock to Lisa Schlesinger, Protara’s newly appointed Vice President, Head of New Product Development and Market Access. Each stock option has an exercise price per share equal to $2.23
- GlobeNewswire
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Tuesday, May 28, 2024 at 3:00 pm ET. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://i
- GlobeNewswire
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBCPreliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024Reached alignment with FDA on registrational path forward for IV Choline Chloride in patients dependent on parenteral nutritionCurrent cash resources, together with approximately $45.0 million in gross proceeds from April 2024 private placement, expected to fund operat
